These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25787058)

  • 1. A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe.
    Giovannoni G; de Jong B; Derfuss T; Izquierdo G; Mazibrada G; Molyneux P; Nicholas R; Overell J; Ziemssen T; Juliusson G
    Mult Scler Relat Disord; 2015 Jan; 4(1):83-4. PubMed ID: 25787058
    [No Abstract]   [Full Text] [Related]  

  • 2. Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?
    Avasarala J; Jain S; Urrea-Mendoza E
    J Clin Pharmacol; 2017 Nov; 57(11):1415-1418. PubMed ID: 28543950
    [No Abstract]   [Full Text] [Related]  

  • 3. Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient.
    Artemiadis AK; Nikolaou G; Kolokythopoulos D; Tegos N; Terentiou A; Triantafyllou N; Papanastasiou I
    Mult Scler; 2015 May; 21(6):795-6. PubMed ID: 25432949
    [No Abstract]   [Full Text] [Related]  

  • 4. [Fingolimod].
    Hashi Y; Kondo T
    Nihon Rinsho; 2015 Sep; 73 Suppl 7():205-11. PubMed ID: 26480701
    [No Abstract]   [Full Text] [Related]  

  • 5. Persistent headache in patients with multiple sclerosis starting treatment with fingolimod.
    Fragoso YD; Adoni T; Gomes S; Goncalves MV; Matta AP; Mendes MF; Siquineli F
    Headache; 2015 Apr; 55(4):578-9. PubMed ID: 25754576
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis.
    Gündüz T; Kürtüncü M; Eraksoy M
    Mult Scler Relat Disord; 2017 Jan; 11():1-3. PubMed ID: 28104247
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use.
    Thoo S; Cugati S; Lee A; Chen C
    Mult Scler; 2015 Feb; 21(2):249-51. PubMed ID: 24696055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggressive cutaneous leishmaniasis in a patient with multiple sclerosis treated with fingolimod.
    Hernández Clares R; Sánchez Pedreño P; García Vazquez E; Carreón Guarnizo E; Meca Lallana JE
    Neurologia (Engl Ed); 2018 Jun; 33(5):348-349. PubMed ID: 28535923
    [No Abstract]   [Full Text] [Related]  

  • 9. Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report.
    Ueda N; Saida K
    BMC Ophthalmol; 2015 Oct; 15():135. PubMed ID: 26481728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herpes zoster: a potential risk associated with fingolimod treatment.
    Mayor Ibarguren A; Gómez Fernández C; Tallón Barranco A; Fernández Fournier M; González Ramos J; Romero Gómez MP; Herranz Pinto P
    Int J Dermatol; 2015 Sep; 54(9):e373-5. PubMed ID: 26173466
    [No Abstract]   [Full Text] [Related]  

  • 11. Primary Cutaneous Cryptococcus in a Patient With Multiple Sclerosis Treated With Fingolimod.
    Forrestel AK; Modi BG; Longworth S; Wilck MB; Micheletti RG
    JAMA Neurol; 2016 Mar; 73(3):355-6. PubMed ID: 26751160
    [No Abstract]   [Full Text] [Related]  

  • 12. Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia.
    Caliendo D; Grassia MC; Carotenuto A; Petracca M; Lanzillo R; Brescia Morra V; Moccia M
    Mult Scler Relat Disord; 2024 Jan; 81():105135. PubMed ID: 38006850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polydermatomal perineal and gluteal herpes zoster infection in a patient on fingolimod treatment.
    Kawiorski MM; Viedma-Guiard E; Costa-Frossard L; Corral I
    Enferm Infecc Microbiol Clin; 2015 Feb; 33(2):138-9. PubMed ID: 24958672
    [No Abstract]   [Full Text] [Related]  

  • 14. Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod.
    Manouchehri N; Mirmosayyeb O; Badihian S; Shaygannejad V
    Mult Scler Relat Disord; 2018 Jan; 19():121-123. PubMed ID: 29195114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphocyte recovery after fingolimod discontinuation in patients with MS.
    Nagy S; Kuhle J; Derfuss T
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32801166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod.
    Stitt DW; Boes CJ; Flanagan EP; Howard MT; Colgan JP
    Mult Scler Relat Disord; 2018 Jan; 19():115-117. PubMed ID: 29190574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
    Flores J; Rito Y; Torres G; Jung H; Treviño-Frenk I; Corona T
    J Neurol Sci; 2015 Jan; 348(1-2):272-3. PubMed ID: 25491264
    [No Abstract]   [Full Text] [Related]  

  • 18. Fingolimod (Gilenya) and melanoma.
    Robinson CL; Guo M
    BMJ Case Rep; 2016 Dec; 2016():. PubMed ID: 28003234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ventricular arrhythmia in a male MS patient on fingolimod.
    van Pesch V; Marchandise S; El Sankari S; Sindic C
    Acta Neurol Belg; 2015 Mar; 115(1):77-9. PubMed ID: 24710722
    [No Abstract]   [Full Text] [Related]  

  • 20. Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod.
    Członkowska A; Smoliński Ł; Litwin T
    Neurol Neurochir Pol; 2017; 51(2):156-162. PubMed ID: 28209440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.